Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Growth Factors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01915602
What this trial is testing

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 14
Not applicableNot Yet RecruitingNCT07113418
What this trial is testing

Role of FGF21 in Breast Cancer

Who this might be right for
Breast Cancer
Assiut University 84
Testing effectiveness (Phase 2)Ended earlyNCT02479490
What this trial is testing

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Who this might be right for
Metastatic Renal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 8
Testing effectiveness (Phase 2)Ended earlyNCT04212650
What this trial is testing

Losartan to Improve Hip Microfracture

Who this might be right for
Hip OsteoarthritisHip Impingement SyndromeCartilage Damage+1 more
Steadman Philippon Research Institute 1
Not applicableEnrolling By InvitationNCT07338097
What this trial is testing

Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema (DME)
CMH Multan Institute of Medical Sciences 116
Large-scale testing (Phase 3)Study completedNCT01940497
What this trial is testing

The Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 240
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Large-scale testing (Phase 3)Ended earlyNCT04066491
What this trial is testing

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Who this might be right for
Biliary Tract CancerCholangiocarcinomaGallbladder Cancer
EMD Serono Research & Development Institute, Inc. 309
Testing effectiveness (Phase 2)Study completedNCT07439068
What this trial is testing

A-PRF and CGF in Palatal Donor Site Healing

Who this might be right for
Free Gingival Graft
Ordu University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Looking for participantsNCT06760819
What this trial is testing

Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Solid TumorsHER2 Mutation
Bayer 111
Early research (Phase 1)Study completedNCT02798991
What this trial is testing

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Who this might be right for
Irritable Bowel Syndrome
GlaxoSmithKline 46
Testing effectiveness (Phase 2)Ended earlyNCT07037420
What this trial is testing

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Who this might be right for
Acromegaly
Alexion Pharmaceuticals, Inc. 8
Not applicableUnknownNCT05983224
What this trial is testing

Effect of Quercetin Supplementation on Endometriosis Outcomes

Who this might be right for
Endometriosis
National Nutrition and Food Technology Institute 50
Large-scale testing (Phase 3)UnknownNCT00683124
What this trial is testing

Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients

Who this might be right for
Marfan Syndrome
Fondazione IRCCS Policlinico San Matteo di Pavia 291
Not applicableStudy completedNCT00059020
What this trial is testing

The Role of Gene Changes in Brain Tumor Formation and Growth

Who this might be right for
Glioma
National Institute of Neurological Disorders and Stroke (NINDS) 344
Not applicableStudy completedNCT04502823
What this trial is testing

Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler

Who this might be right for
Fetal Growth Retardation
Hospital Universitari Vall d'Hebron Research Institute 1,088
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Not applicableUnknownNCT04817878
What this trial is testing

Cohort Construction for Preterm Infants With Growth Retardation and Its Influencing Factors

Who this might be right for
Problem With Growth of an Infant
Peking University Third Hospital 2,400
Testing effectiveness (Phase 2)Study completedNCT00913835
What this trial is testing

Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Eli Lilly and Company 125
Next Page